Does a better 2:16 ratio mean better health?

Not demonstrated. In the largest trial the ratio improved while clinical biomarkers did not.

Is DIM safe with the pill?

Discuss it first. DIM alters oestrogen metabolism and CYP enzyme activity, both of which can affect contraceptive exposure.

Do men benefit from DIM?

The trial evidence is in women. Claims about male oestrogen balance are extrapolation, not tested findings.

Outcome

Limited

Effectiveness 3/5

DIM for Estrogen Balance

DIM (diindolylmethane, from cruciferous vegetables) shifts estrogen metabolism toward the less proliferative 2-hydroxy pathway and improved metabolite ratios in human trials.

Overview

The largest DIM trial to date is instructive because it did two things at once. In 130 women taking tamoxifen, DIM raised the urinary 2:16-alpha-hydroxyoestrone ratio as intended, but it also lowered endoxifen concentrations and produced no favourable change in mammographic density or other clinical biomarkers.

So the biochemical claim holds: DIM reliably shifts oestrogen metabolism in the expected direction. The clinical claim does not follow from it, and in this trial the surrogate marker improved while nothing that matters clinically did. That is the honest framing of oestrogen balance with DIM. It is a demonstrated metabolic shift with unproven downstream benefit, plus one clear signal of harm potential through interference with a widely used medicine.

Verdict

Likely effective

A 130-participant randomised trial confirmed the metabolic ratio shift but found no clinical biomarker benefit and a reduction in active tamoxifen metabolite.

How It Works

DIM binds the aryl hydrocarbon receptor and induces CYP1A1, steering oestradiol clearance toward 2-hydroxyoestrone rather than the more oestrogenic 16-alpha-hydroxy metabolite. This is the whole of its accepted mechanism in humans.

The same enzyme induction explains the tamoxifen finding. Tamoxifen requires CYP-mediated conversion to endoxifen, its active form, and altering that enzymatic environment changed how much active drug the participants had. A mechanism broad enough to redirect your own hormone metabolism is broad enough to redirect drug metabolism. Those are not two separate facts about DIM; they are the same fact seen from two angles.

Primary target: Aryl hydrocarbon receptor and CYP1A1 induction
Confirmed effect: Increased urinary 2:16-alpha-hydroxyoestrone ratio
Unconfirmed: Mammographic density and other clinical biomarkers unchanged
Known off-target effect: Reduced endoxifen in tamoxifen users
Best-fit user: Adults not on hormone-modulating medication, tracking the ratio

Dosing & Protocol

Doses across trials run from around 108 to 300 mg daily of absorption-enhanced DIM. Because formulations differ several-fold in absorption, the product technology matters as much as the number on the label.

Context	Dose	Form	Timing
Larger trial dose	300 mg daily	Absorption-enhanced DIM	Split into two doses with food
Typical commercial dose	100-200 mg daily	Microencapsulated DIM	Once daily with a meal
Lower pilot dose	108 mg daily	Enhanced formulation	Once daily
Assessment window	12 weeks or more	Enhanced formulation	Daily

1
Screen your medication list first· Before starting
Tamoxifen, hormonal contraceptives and CYP-metabolised drugs all make this a clinician decision.
2
Define the endpoint honestly· Week 0
The ratio will likely move. Decide in advance whether a marker shift alone is worth it to you.
3
Use 100-200 mg daily with food· Weeks 1-12
Higher doses have not been shown to deliver better clinical results.
4
Track symptoms alongside the marker· Weeks 1-12
The largest trial found marker change without clinical change; your own log is the check on that.
5
Review at 12 weeks· Week 12
Continue only if something you actually care about improved.

Do not combine with tamoxifen on your own

The largest randomised trial found DIM lowered endoxifen, tamoxifen's active metabolite. That is a potential reduction in treatment effectiveness, not a theoretical concern.

Evidence

The linked randomised placebo-controlled trial is the most informative study in this area, and the most sobering. It confirmed the metabolic mechanism while showing that neither mammographic density nor other clinical biomarkers improved, and it identified a clinically significant drug interaction.

Randomised placebo-controlled trial linked to this pairing.

A Randomized, Placebo-Controlled Trial of Diindolylmethane for Breast Cancer Biomarker Modulation in Patients Taking Tamoxifen

Score: 8/10

2017

rct

n=130

Thomson CA, Chow HHS, Wertheim BC +5 more

DIM increased the urinary 2:16-alpha-hydroxyoestrone ratio and lowered endoxifen concentrations.

View source

Best available evidence: Randomised placebo-controlled trial, n=130
Confirmed effect: Increased urinary 2:16-alpha-hydroxyoestrone ratio
Null findings: No improvement in mammographic density or clinical biomarkers
Studied dose: Absorption-enhanced DIM, up to 300 mg daily
Main limitation: Conducted in tamoxifen users; endoxifen reduction limits generalisability

Safety

Direct side effects are usually mild: headache, nausea, gas and dark urine. The more important safety consideration is the pharmacokinetic one, because a supplement that changes drug levels can cause harm without causing symptoms.

Cautions

Lowers endoxifen in tamoxifen users

Harmless dark urine discolouration

Headache, nausea and bloating

Avoid in pregnancy and breastfeeding

Marker improvement did not translate to clinical benefit in the largest trial

Interactions & Conflicts

Every meaningful DIM interaction traces back to cytochrome P450 induction. If a medicine you take depends on those enzymes for activation or clearance, DIM is a genuine variable rather than a background supplement.

Interacts with	Severity	Mechanism	Action
Tamoxifen	high	Reduced conversion to active endoxifen	Avoid unless your oncologist explicitly approves
Hormonal contraceptives	moderate	Altered oestrogen metabolism may reduce exposure	Discuss with your prescriber before starting
CYP1A2 and CYP3A4 substrates	moderate	Enzyme induction shifts drug levels	Have a pharmacist review your list
Aromatase inhibitors	moderate	Overlapping hormonal effects, unstudied in combination	Only under specialist supervision

References

Thomson CA et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Res Treat. 2017

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.